Onyx Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapies that target the molecular mechanisms implicated in cancer in the United States. Its primary product includes Nexavar, a small molecule inhibitor of tumor cell proliferation and angiogenesis for the treatment of individuals with advanced kidney cancer targeting RAF, VEGFR-1, VEGFR-2, VEGFR-3, PDGFR-ß, KIT, FLT-3, and RET. The company also develops a Phase I clinical trial product, PD 332991, a small molecule inhibitor of cyclin-dependent kinase 4 for the treatment of multiple cancer types. It has collaboration agreements with Bayer Pharmaceuticals Corporation to discover, develop, and market compounds that inhibit the function, or modulate the activity, of the RAS signaling pathway to treat cancer and other diseases; and Warner-Lambert Company to discover and commercialize small molecule drugs that restore control of, or intervene in, the misregulated cell cycle in tumor cells. The company was founded in 1992 and is headquartered in Emeryville, California.